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Abstract
Background: Whilst much attention is given to eliminating HIV mother-to-child transmission (MTCT), little has been
done to ensure the same for hepatitis B virus (HBV) transmission. The introduction of HBV immunization at six
weeks of age has reduced HBV horizontal transmission in South Africa. However, in order to eliminate HBV MTCT,
further interventions are needed. The risk of hepatitis C virus (HCV) MTCT in HIV-infected (HIV+) African women is
not yet well described. This study aimed to determine the rate of HBV and HCV vertical transmission in HIV-exposed
infants in South Africa.
Methods: Serum samples from infants enrolled in an isoniazid prevention study (P1041) were screened for HBV and
HCV serology markers; screening was performed on samples collected at approximately 60 weeks of age of the
infants. HBV DNA was quantified in HBsAg positive samples and HBV strains characterized through gene
sequencing. All HCV antibody samples with inconclusive results underwent molecular testing.
Results: Three of 821 infants were positive for both HBsAg and HBV DNA. All HBV strains belonged to HBV sub-
genotype A1. The rtM204I mutation associated with lamivudine resistance was identified in one infant, a second
infant harboured the double A1762T/G1764A BCP mutation. Phylogenetic analysis showed clustering between
mother and infant viral genomic sequences. Twenty-one of 821 HIV-exposed infants tested had inconclusive HCV
antibody results, none were HCV PCR positive.
Conclusions: This study suggests that HBV vertical transmission is likely to be occurring in HIV-exposed infants in
South Africa.. A more robust strategy of HBV prevention, including birth dose vaccination, is required to eradicate
HBV MTCT. HCV infection was not detected.
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Background
Persistent viral hepatitis is a major public health prob-
lem and a major cause of infectious disease mortality,
similar to HIV, malaria and tuberculosis [1]. Globally,
hepatitis B (HBV) and hepatitis C (HCV) viruses affect
an estimated 257 million and 71 million individuals,
respectively. Sub-Saharan Africa (SSA), where the preva-
lence of chronic HBV infection is estimated at over 8%,
and the Western Pacific region bear the greatest burden
of HBV whilst HCV prevalence is highest in North Af-
rica [2, 3].
Early regional studies in SSA described high HBV sur-
face antigen (HBsAg) prevalence rates in children older
than one year but low rates in infancy, implicating hori-
zontal transmission at or after the neonatal period as the
major route of transmission [4, 5]. These data informed
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the current policy of routine infant immunisation com-
mencing at six weeks of age in many sub-Saharan Afri-
can countries. Although this strategy led to a decrease in
HBV infection in children [6], infants are still infected
during the perinatal period [7]. HBV acquired during
childhood carries a high risk for persistent infection and
consequent severe liver disease. World Health
Organization (WHO) guidelines recommend that the
first dose of HBV vaccine be given shortly after delivery
[8]; this is especially important in highly endemic re-
gions such as SSA and the Western Pacific, where HBV
mother-to-child transmission (MTCT) and early child-
hood transmission predominate. While implementation
of this practice in the Western Pacific region has re-
duced both HBV MTCT and early childhood infections
[9], HBV MTCT remains a concern in SSA [7]. Al-
though current data suggest that immunisation starting
at six weeks of age has reduced the prevalence of persist-
ent HBV infection [6], the impact of HIV on HBV
mother-to-child transmission (MTCT) in SSA is not well
described. Moreover, little is known about the preva-
lence of persistent viral hepatitis in HIV-infected (HIV+)
children.
About 1.96 million of 36.7 million HIV + individuals
(~ 5.3%) in SSA are co-infected with HBV [10]. Of con-
cern is the high prevalence of HBV e-antigen (HBeAg)
in HIV + pregnant women [11]. In a recent Malawian
study, 38.2% of 102 HIV/HBV co-infected women of
childbearing age were HBeAg positive [12]. HBeAg
prevalence rates of 18.9% (10/53) and 37.5% (6/16) have
been reported in South Africa [13, 14]. HBeAg positivity
is associated with higher HBV viral loads and increased
risk of HBV MTCT [15]. In pregnancy, HBeAg positivity
carries a 90% risk of HBV MTCT compared to 25% for
HBeAg negative women [16]. Prevention of HIV MTCT
(PMTCT) guidelines recommend routine HIV testing
for all pregnant women with unknown HIV status. How-
ever, as HBV antenatal screening is not routinely per-
formed in many parts of SSA, the extent of perinatal
HBV transmission in the HIV era remains under-
investigated. Whilst there is some epidemiological data
in blood donors and antenatal cohorts, there are few re-
ports in children [17].
HCV prevalence is considered low in SSA [18], but lit-
tle is known about HCV in pregnancy and in children,
in particular in those who are HIV co-infected. This
study aimed to establish the prevalence of HBV and




This was a retrospective study using residual samples
from the P1041 trial through the International Maternal
Paediatric Adolescent AIDS Clinical Trial (IMPAACT)
Group. P1041 was a multi-centre, Phase II-III random-
ized, double blind, placebo-controlled trial to determine
the efficacy of isoniazid in preventing tuberculosis (TB)
disease and latent TB infection among infants perinatally
exposed to HIV [19]. From December 2004 to June
2008, 1354 infants born to HIV +mothers in South Afri-
can sites including Cape Town, Durban, and Johannes-
burg, and Gaborone in Botswana were enrolled in the
P1041 study. Among these 1354 infants, 548 were HIV-
infected and 806 were HIV-uninfected. Collection of
data and blood samples occurred at three time points: at
study entry, which corresponded to approximately 12
weeks of age (“Week 0” on study), at ~ 24 weeks of age
(“Week 12” on study) and ~ 60 weeks of age (“Week 48”
on study). The HBV infection status of the mothers was
unknown.
Available plasma and serum samples from “Week 48”
from the South African sites were screened for active
HBV and HCV infections. Samples collected at earlier
time points (i.e. “Week 0” and “Week 12”) from infants
found HBsAg positive at “Week 48” were tested for ac-
tive HBV infection, and attempts were made to trace all
HBsAg positive infants and their mothers for serological
and molecular follow-up testing. Universal HBV immun-
isation at 6, 10 and 14 weeks of age was introduced in
South Africa in 1995, preceding the P1041 trial by nine
years.
Serological screening
Given the limited sample volumes available, serological
testing was done at 1:10 dilution in normal human
plasma, on the Abbott ARCHITECT i2000SR automated
platform (Abbott Diagnostics, Delkenheim, Germany),
following previous validation (data not shown).
Samples were tested for HBsAg, anti-HBs, anti-HBc
(total) and anti-HCV using the ARCHITECT i2000SR
system, according to manufacturer’s instructions. HBsAg
positive samples were tested for HBeAg and anti-HBe
using the ARCHITECT HBeAg and anti-HBe chemilu-
minescent immunoassays. Anti-HBs titre ≥ 10 IU/mL is
the accepted threshold for protective immunity against
HBV. Samples with anti-HBs titres below 1 IU/ml were
recorded anti-HBs negative. Samples with anti-HBs
levels falling between 10 IU/ml and 100 IU/ml, indicator
low level of immune protection against HBV, were also
recorded.
Quantification of HBV DNA
Viral DNA was extracted from 200 µl of serum samples
using the QIAamp® MinElute® Virus Spin kit (QIAGEN,
Hilden, Germany). Extracted HBV DNA was amplified
and quantified, using a probe-based real-time PCR assay
on the RotorGene™ 6000 (Corbett Life Sciences,
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Australia), at the following cycling conditions: initial de-
naturation for 15 minutes at 95 °C followed by 45 cycles
of 95 °C for 15 seconds and 60 °C for 60 seconds [20].
Sequences of the primers and probes used in the assay
were as described by Garson et al. (2005) [20].
Quantification of HCV RNA
Viral nucleic acid extraction and quantification were
performed using the COBAS® AmpliPrep/COBAS® Taq-
Man® HCV Test (Roche Molecular Diagnostics, Almere,
Netherlands), according to manufacturer’s instructions.
HBV DNA sequencing
DNA positive samples underwent sequencing of the poly-
merase/surface and core genomic regions [21, 22]. Gen-
omic sequences were submitted to the National Center
for Biotechnology Information HBV Genotyping tool
(http://hivdb.stanford.edu/HBV/HBVseq/development/
HBVseq.html) and to Geno2Pheno (http://hbv.geno2
pheno.org/index.php) for HBV genotyping and to detect
immune escape and drug resistance mutants, respectively.
Phylogenetic analysis
The relationship between maternal and children viral se-
quences was inferred using a Maximum Likelihood
phylogenetic tree constructed using a bootstrap of 1000
replicates in MEGA 7 [23]. Evolutionary distances be-
tween the query sequences were calculated using the
General Time Reversible model [24].
Results
The study population comprised of 821 infants from
Cape Town, Durban, and Johannesburg with plasma
samples available from “Week 48”. Baseline demograph-
ics and HIV clinical characteristics are outlined in
Table 1.
Active HBV infection screening
Among screened samples, three samples were positive
for HBsAg and HBV DNA (3/821, 0.4%), of which two
were from HIV + infants and the other from an HIV ex-
posed uninfected infant, one each from Cape Town, Jo-
hannesburg, and Durban. Five samples were anti-HBc
(total) reactive (5/821, 0.6%); of these, three were also
HBsAg positive while the other two were HBsAg nega-
tive. Insufficient sample volume prevented HBeAg and
anti-HBe testing (Table 2). Sequencing of the HBV poly-
merase/surface and core genomic regions showed sub-
genotype A1 strains. Sequence analysis revealed the
M204I mutation in the reverse transcriptase domain of
the polymerase gene in the Durban sample while the
Cape Town sample harboured the double A1762T/
G1764A BCP mutation in the core gene. No HBV muta-
tion was found in the Johannesburg sample.
Retrospective serological and molecular testing
One HBsAg positive infant (Cape Town) had been
immunised against HBV, while there were no records of
HBV immunisation for the Durban and Johannesburg
HBsAg positive infants. Samples from earlier time points
were retrieved for the Durban and Cape Town infants
and were screened for active HBV infection. Sample vol-
ume was sufficient for serological and molecular screen-
ing for the “Week 0” Cape Town sample and molecular
testing only for the “Week 0” and “Week 24” Durban
samples. All three samples were HBV DNA positive.
The “Week 0” Cape Town sample showed a similar
serological profile to the “Week 48” sample from the
same child and also had the double A1762T/G1764A
BCP mutation. Insufficient sample volume precluded
testing the Johannesburg infant.
Follow-up
Two HBsAg positive infants (Durban and Johannesburg)
could not be traced, but the HBsAg positive infant from
Cape Town was traced and reviewed seven years after
the “Week 48” screening assessment, at 8 years of age.
This child was HIV + and receiving stavudine (D4T),
lamivudine (3TC) and lopinavir/ritonavir (LPV/r) while
the mother was on 3TC, tenofovir (TDF) and LPV/r.
Follow-up serological and molecular testing
Samples from both mother and child were HBsAg posi-
tive, HBeAg negative/anti-HBe positive at follow up.
















On ART at sample collectionb
Yes 259 (82%)
No 56 (18%)
aAssessed as of date of sample collection at Study “Week 48”; bART:
combination Antiretroviral Therapy, defined as being on at least 3 drugs in at
least 2 classes
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While the child sample had an undetectable HBV viral
load, low level HBV DNA was detected in the maternal
sample (HBV viral load = 19 IU/ml). Owing to the low
maternal viral load, only core sequencing was successful.
A comparison of the maternal and the “Week 48” infant
HBV core sequences showed similarity in protein/nu-
cleotide sequences (99% homology). Both sequences har-
boured the double A1762T/G1764A BCP mutation.
Phylogenetic analysis showed close clustering between
the maternal and child sequences (Fig. 1).
HBV immunity screening
HBV immunity, demonstrated by the presence of anti-
HBs only, was assessed in all 821 samples. Seroprotective
levels of anti-HBs ≥ 10 IU/ml were found in 745/821
samples (90.7%); of which 277 (37.2%) had anti-HBs
levels < 100 IU/ml. The remaining 76 (9.3%) samples had
anti-HBs levels < 10 IU/ml; of which 14 samples (1.7%)
were anti-HBs negative (< 1 IU/ml). Among the five
anti-HBc (total) reactive samples, the two HBsAg nega-
tive samples had anti-HBs levels above 100 IU/ml while
the three HBsAg positive samples had anti-HBs levels
below 10 IU/ml.
HCV infection screening
All 813 “Week 48” samples tested for anti-HCV
were negative. However, 21 samples showed S/CO
values > 0.10; this was thought to be due to non-
specific reactivity. In order to address the possibility
that antibody response may have been impaired and
low, HCV RNA testing was undertaken on 16/21
samples with sufficient volume available, with nega-
tive results.
Table 2 Serological and molecular results of HBV-infected children at screening and follow-up
Patient Location HBV vaccination HIV Status Screening Prospective follow-up
HBsAg HBV DNA log 10 (IU/ml) HBsAg HBeAg Anti-HBe HBV DNA (IU/ml)
C1a CPT Yes + + 8.93 + - + UD
C2 Durban No record + + 5.17 ND ND ND ND
C3 JHB No record - + 8.45 ND ND ND ND
aTherapy: D4T, 3TC & KLT (at follow-up); Anti-HBe antibody to hepatitis B e antigen, C Child, CPT Cape Town, IU/ml International Units per milliliter, HBeAg hepatitis
B e antigen, HBsAg hepatitis B surface antigen, JHB Johannesburg, − Negative, + Positive, ND Not done, UD Undetectable
Fig. 1 Phylogenetic tree of HBV-infected infants and Cape Town mother based on the HBV core region. Sequences with accession numbers
starting with JX and KF were downloaded from GenBank. The evolutionary history was inferred by using the Maximum Likelihood method based
on the General Time Reversible model with 1000 bootstrap replicates. A discrete Gamma distribution [25] was used to model evolutionary rate
differences among sites
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Discussion
In this cohort of infants born to HIV +mothers, three
infant samples were HBsAg positive at “Week 48”, giving
a 0.4% prevalence of active infection (3/821). Testing for
anti-HBc (total) showed that a further two infant sam-
ples (2/821, 0.2%) showed the presence of anti-HBc
(total) levels greater than the assay’s cut-off (> 1 S/CO),
suggesting past infection to HBV. On repeat testing the
Cape Town case revealed persistent HBV infection with
a strain closely related to the maternal HB virus. This
was despite infant HBV immunisation. The other two
cases could not be traced.
In South Africa, HBV immunisation from six weeks of
age was implemented in the mid-1990s as HBV trans-
mission was thought to be predominantly horizontal [4,
26, 27]. This intervention led to a decrease in HBsAg
prevalence rate from approximately 10% [28] to between
0% and 2.7% [29–33]. A pre- versus post-HBV
immunization analysis of 1206 children aged 1 to
25 years in South Africa showed an HBsAg prevalence
rate declining from 4.2–1.4%, and prevalence of HBV
immunity increasing from 13–57% [6]. Although HBV
immunisation was documented in only 16% (129/821) of
our cohort, 90.6% (745/821) had protective anti-HBs
levels, suggesting poor documentation rather than defi-
ciencies in immunisation coverage.
Although the prevalence of HBV infection in child-
hood has declined, HBV perinatal transmission remains
a concern. Delay in seroconversion to anti-HBe, reacti-
vation of HBe antigenemia and sero-reversion to HBsAg
positivity, indicative of increased HBV replication
through HIV-induced immunosuppression, are well de-
scribed in HIV + patients [34, 35]. High HBsAg and
HBeAg prevalences with high HBV replication activity
have been described in HIV + South African women
[13]. Furthermore, a study from Soweto described four
cases of perinatal transmission from 14 HIV +mothers.
Three of the four infants were born to HBeAg positive
mothers with HBV viral load of 1.995E + 8 IU/ml,
6.309 IU/ml and 100 IU/ml HBV DNA [36].
The present study showed a HBsAg prevalence (0.4%,
3/820) similar to that in 1000 HIV-exposed infants from
the Western Cape’s PMTCT program [37]. In both stud-
ies, HBV immunisation starting at six weeks of age failed
to prevent all HBV MTCT.
It is well established that HBV immunisation at birth
alone is effective in preventing HBV perinatal transmis-
sion from some HBV-infected women [38–40] but is
only partially protective for infants born to mothers with
high HBV viral loads [41]. Giving hepatitis B immuno-
globulin (HBIG) together with HBV birth vaccine, ac-
tive/passive immunisation further reduces the risk of
HBV MTCT [38, 42, 43], but is costly and not logistic-
ally possible in many resource-limited settings. Treating
women in the third trimester of pregnancy with antiviral
drugs such as lamivudine [44], tenofovir [45] or telbivu-
dine [46] is effective in reducing HBV viral load and thus
reducing the risk of transmission. Tenofovir and emtrici-
tabine (or lamivudine) have been part of first-line ante-
natal antiretroviral therapy (ART) in SSA since 2010, so
HIV-HBV co-infected pregnant women would have re-
ceived anti-HBV therapy. However, HBV mono-infected
pregnant women remain unidentified and untreated,
leaving their infants at risk of acquiring HBV from their
mothers.
The other interesting aspect of these results is to con-
sider the 2/5 anti-HBc (total) reactive samples, which
may indicate exposure to HBV infection, but may also
reflect residual maternal antibody.
No HCV infection was identified in this study. HCV
prevalence is considered low in SSA (< 1%) [18]. How-
ever, there is little published data from paediatric co-
horts in this region. Further work is required to confirm
the findings of this study.
While this study adds to our understanding of HBV
epidemiology in South African infants, there are limita-
tions in the interpretation of these results. The absence
of ART data on mothers prevented assessing the effect
of maternal ART on the HBV infection risk to infants.
However, during the study period, TDF and emtricita-
bine (FTC) were unavailable and only HIV +mothers
with a CD4 + T-cell count below 200 per mm3 were eli-
gible for lamivudine-containing ART, which would have
reduced the risk of HBV transmission. Currently in
South Africa all HIV + women have access to ART con-
taining TDF and lamivudine or FTC. In the absence of
HBV screening in pregnancy, the risk of replacing teno-
fovir to a second- or third-line ART may not be appreci-
ated. Maternal HBV status would have allowed
calculation of a definitive risk of perinatal transmission
but was unavailable. Limited immunisation records com-
promised the interpretation of anti-HBs levels. Finally,
as the samples were collected more than seven years ago
from three different locations, loss to follow-up pre-
vented further assessment of two of the HBsAg positive
cases.
Conclusions
This study shows evidence of HBV infections in infants
born to HIV +mothers. No HCV infection was detected
in this large cohort of HIV-exposed infants in South Af-
rica. In order to eliminate HBV MTCT, a combination
of strategies including HBV screening, together with ma-
ternal antiviral therapy and most importantly HBV im-
munisation at the time of birth will be required. These
strategies, although well described, require further SSA
data to assess the cost effectiveness ultimately to elimin-
ate this route of HBV infection.
Tamandjou Tchuem et al. BMC Pediatrics          (2020) 20:563 Page 5 of 7
Abbreviations
3TC: Lamivudine; Anti-HBc (total): Total antibodies against hepatitis B core
antigen; Anti-HBe: Antibodies against hepatitis B e antigen; Anti-
HBs: Antibodies against hepatitis B surface antigen; Anti-HCV: Antibodies
against hepatitis C virus; ART: Antiretroviral therapy; BCP: Basal Core
Promoter; CD4 + T-cell: Type CD4 + T cell; D4T: Stavudine;
DNA: Deoxyribonucleic acid; FTC: Emtricitabine; HBeAg: Hepatitis B e antigen;
HBsAg: Hepatitis B surface antigen; HBV: Hepatitis B infection; HCV: Hepatitis
C virus; HIV: Human Immunodeficiency Virus; LPV/r: Lopinavir/ritonavir;
MTCT: Mother-to-child transmission; PMTCT: Prevention of mother-to-child
transmission; RNA: Ribonucleic acid; SSA: Sub-Sahara Africa; TB: Tuberculosis;
TDF: Tenofovir Disoproxil Fumarate; VL: Viral load; WHO: World Health
Organization
Acknowledgements
Our sincere gratitude goes to the study participants and the IMPAACT group
for allowing access to these samples and the study team for all their efforts
throughout this study and in the writing of this manuscript.
Authors’ contributions
Study conceptualization and design: MFC, AV, and MIA. Funding acquisition:
MFC and MIA. Methodology: CTT, RT, WP, and MIA. Validation: CTT, RT, and
MIA. Resources: RT, AV, RB, LH, LA, GM, CM, MIA. Project administration: CTT,
MFC, and MIA. Data collection and investigation: CTT. Data analysis and
interpretation: CTT, RT, EN, WP, and MIA. Visualization: CTT. Supervision: WP
and MIA. Manuscript original drafting: CTT, MFC, WP, and MIA. Critical review
and manuscript revision: CTT, MFC, EN, RT, WP, AV, RB, LH, LA, GM, CM, and
MIA. All authors read and approved the final version of the manuscript.
Funding
The study was financially sponsored by the National Health Laboratory
Service Research Trust, the Poliomyelitis Research Foundation, and the Harry
Crossley Foundation to support materials, reagents, and laboratory testing.
Overall financial support for the International Maternal Pediatric Adolescent
AIDS Clinical Trials Network (IMPAACT) was provided by the National
Institute of Allergy and Infectious Diseases (NIAID) with co-funding from the
Eunice Kennedy Shriver National Institute of Child Health and Human Devel-
opment (NICHD) and the National Institute of Mental Health (NIMH), all com-
ponents of the National Institutes of Health (NIH), under Award Numbers
UM1AI068632 (IMPAACT LOC), UM1AI068616 (IMPAACT SDMC) and
UM1AI106716 (IMPAACT LC), and by NICHD contract number
HHSN275201800001I. The funders had no participation in the design, data
collection and analysis, interpretation of the results of this study and in writ-
ing of the manuscript.
Availability of data and materials
The datasets during and/or analysed during the current study are available
from the corresponding author on reasonable request.
Ethics approval and consent to participate
Ethics approval was received from the Health Research Ethics Committees of
Stellenbosch University (N10/04/115) and the University of Witwatersrand
(020109), and the Biomedical Research Ethics Committee of the University of
Kwazulu-Natal (T118/05). Mothers included in the original P1041 study also
provided informed written consent, prior inclusion, for testing of other infec-
tions that affect people with HIV (including hepatitis viruses). Written in-
formed consent was obtained from parents or legal guardians for babies and




The authors declare that they have no financial or personal interest(s) which
may have inappropriately influenced them during the conduct of this
research study and in writing this article.
Author details
1Division of Medical Virology, Department of Pathology, Faculty of Medicine
and Health Sciences, Stellenbosch University, Cape Town, South Africa.
2Department of Paediatrics & Child Health, Faculty of Medicine and Health
Sciences, FAM-CRU, Stellenbosch University, Cape Town, South Africa.
3Department of Paediatrics & Child Health, Faculty of Medicine and Health
Sciences, Stellenbosch University, Cape Town, South Africa. 4Blood Borne
Viruses Unit, Virus Reference Department, Public Health England, London, UK.
5Perinatal HIV Research Unit, University of the Witwatersrand, Johannesburg,
South Africa. 6Department of Paediatrics, Nelson R. Mandela School of
Medicine, University of KwaZulu Natal, Durban, South Africa. 7Frontier
Science and Technology Research Foundation, New York, USA. 8Center for
Biostatistics in AIDS Research, Harvard T.H. Chan School of Public Health,
Boston, Massachusetts, USA. 9Department of Paediatrics, School of Medicine,
University of Miami Miller, Miami, USA. 10Department of Microbiology and
Infectious Diseases, Oxford University Hospitals NHS Foundation Trust,
Oxford, UK.
Received: 6 July 2020 Accepted: 17 December 2020
References
1. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global
and regional mortality from 235 causes of death for 20 age groups in 1990
and 2010: a systematic analysis for the Global Burden of Disease Study
2010. Lancet. 2013;380:2095–128. https://doi.org/10.1016/S0140-
6736(12)61728-0.
2. World Health Organization. Hepatitis B. 2019. http://www.who.int/
mediacentre/factsheets/fs204/en/. (Accessed 09 Feb 2018).
3. World Health Organization. Hepatitis C. 2019. http://www.who.int/
mediacentre/factsheets/fs164/en/. (Accessed 09 Feb 2018).
4. Prozesky OW, Szmuness W, Stevens CE, Kew MC, Harley EJ, Hoyland JA,
et al. Baseline epidemiological studies for a hepatitis B vaccine trial in
Kangwane. S Afr Med J. 1983;64:891–3.
5. Botha JF, Dusheiko GM, Ritchie MJJ, Mouton HW, Kew MC. Hepatitis B virus
carrier state in black children in Ovamboland: role of perinatal and
horizontal infection. Lancet. 1984;323:1210–2. https://doi.org/10.1016/S0140-
6736(84)91694-5.
6. Amponsah-Dacosta E, Lebelo RL, Rakgole JN, Burnett RJ, Selabe SG,
Mphahlele MJ. Evidence for a change in the epidemiology of hepatitis B
virus infection after nearly two decades of universal hepatitis B vaccination
in South Africa. J Med Virol. 2014;86:918–24. https://doi.org/10.1002/jmv.
23910.
7. Keane E, Funk AL, Shimakawa Y. Systematic review with meta-analysis: the
risk of mother-to-child transmission of hepatitis B virus infection in sub-
Saharan Africa. Aliment Pharmacol Ther. 2016;44:1005–17. https://doi.org/10.
1111/apt.13795.
8. World Health Organization. Hepatitis B vaccines: WHO position paper – July
2017. Wkly Epidemiol Rec. 2017;27:369–92.
9. Woodring J, Pastore R, Brink A, Ishikawa N, Takashima Y, Tohme RA.
Progress Toward Hepatitis B Control and Elimination of Mother-to-Child
Transmission of Hepatitis B Virus - Western Pacific Region, 2005–2017. Morb
Mortal Wkly Rep. 2019;68:195–200. 10.15585/mmwr.mm6808a2.
10. World Health Organization. Global hepatitis report, 2017. 2018 https://apps.
who.int/iris/bitstream/handle/10665/255016/9789241565455-eng.
pdf?sequence=1. (Accessed 22 Mar 2018).
11. Andersson MI, Maponga TG, Ijaz S, Theron G, Preiser W, Tedder RS. High
HBV viral loads in HIV-infected pregnant women at a tertiary hospital, South
Africa. J Acquir Immune Defic Syndr. 2012;60:e111-2. https://doi.org/10.
1097/QAI.0b013e31825aeee7.
12. Chasela CS, Kourtis AP, Wall P, Drobeniuc J, King CC, Thai H, et al. Hepatitis
B virus infection among HIV-infected pregnant women in Malawi and
transmission to infants. J Hepatol. 2014;60:508–14. https://doi.org/10.1016/j.
jhep.2013.10.029.
13. Andersson M, Maponga T, Ijaz S, Barnes J, Theron GB, Meredith SA, et al.
The epidemiology of hepatitis B virus infection in HIV-infected and HIV-
uninfected pregnant women in the Western Cape, South Africa. Vaccine.
2013;31:5579–84. https://doi.org/10.1016/j.vaccine.2013.08.028.
14. Thumbiran NV, Moodley D, Parboosing R, Moodley P. Hepatitis B and HIV
co-infection in pregnant women: Indication for routine antenatal hepatitis B
virus screening in a high HIV prevalence setting. S Afr Med J. 2014;104:307–
9. https://doi.org/10.7196/SAMJ.7299.
15. Burnett RJ, Ngobeni JM, François G, Hoosen AA, Leroux-Roels G, Meheus A,
et al. Increased exposure to hepatitis B virus infection in HIV-positive South
Tamandjou Tchuem et al. BMC Pediatrics          (2020) 20:563 Page 6 of 7
African antenatal women. Int J STD AIDS. 2007;18:152–6. https://doi.org/10.
1258/095646207780132523.
16. Umar M, Hamama-Tul-Bushra, Umar S, Khan HA. HBV Perinatal Transmission.
. Int J Hepatol. 2013;2013:875791–7. https://doi.org/10.1155/2013/875791.
17. Mora N, Adams WH, Kliethermes S, Dugas L, Balasubramanian N, Sandhu J,
et al. A synthesis of hepatitis C prevalence estimates in sub-Saharan Africa:
2000–2013. BMC Infect Dis. 2016;16:283. https://doi.org/10.1186/s12879-016-
1584-1.
18. Karoney MJ, Siika AM. Hepatitis C virus (HCV) infection in Africa: a review.
Pan Afr Med J. 2013;14:44. https://doi.org/10.11604/pamj.2013.14.44.2199.
19. Madhi SA, Nachman S, Violari A, Kim S, Cotton MF, Bobat R, et al. Primary
isoniazid prophylaxis against tuberculosis in HIV-exposed children. N Engl J
Med. 2011;365:21–31. https://doi.org/10.1056/NEJMoa1011214.
20. Garson JA, Grant PR, Ayliffe U, Ferns RB, Tedder RS. Real-Time PCR.
Quantitation of Hepatitis B Virus DNA using Automated Sample Preparation
and Murine Cytomegalovirus Internal Control. J Virol Methods. 2005;126:
207–13. https://doi.org/10.1016/j.jviromet.2005.03.001.
21. Dervisevic S, Ijaz S, Chaudry S, Tedder RS. Non-A hepatitis B virus genotypes
in antenatal clinics, United Kingdom. Emerg Infect Diseases. 2007;13:1689–
93. https://doi.org/10.3201/eid1311.070578.
22. Public Health England. Recommended Protocol for HBV genotyping and for
antiviral resistance analysis. 2007. https://www.gov.uk/government/uploads/
system/uploads/attachment_data/file/342414/cfi_vrd_
PolHBsAgRecommendationsFINAL_HBV_protocol.pdf. (Accessed 09 Feb
2018).
23. Tamura K, Stecher G, Peterson D, Filipski A, Kumar S. MEGA6: Molecular
Evolutionary Genetics Analysis version 6.0. Mol Biol Evol. 2013;30:2725–9.
https://doi.org/10.1093/molbev/mst197.
24. Tavaré S. Some probabilistic and statistical problems in the analysis of DNA
sequences. In: Miura RM, editor. Some Mathematical Questions in Biology -
DNA Sequence Analysis. Providence: Amer Math Soc; 1986. p. 57–86.
25. Yang Z. Maximum likelihood phylogenetic estimation from DNA sequences
with variable rates over sites: approximate methods. J Mol Evol. 1994;39:
306–14. https://doi.org/10.1007/BF00160154.
26. Vos GH, Rose EF, Marimuthu T. Hepatitis B, Antigen. and Antibodies in Rural
and Urban Southern African Blacks. S Afr Med J. 1980;57:868–70.
27. Abdool Karim SS, Coovadia HM, Windsor IM, Thejpal R, Van Den Ende JA,
Fouche A. The Prevalence and Transmission of Hepatitis B Virus Infection in
Urban, Rural and Institutionalized Black Children of Natal/KwaZulu, South
Africa. Int J Epidemiol. 1988;17:168–73. https://doi.org/10.1093/ije/17.1.168.
28. Kew M, Miller G, Stevenson C, Macnab GM, Bersohn I. The Prevalence of
Virus-B Hepatitis South African Blacks. S Afr Med J. 1974;48:1837–8.
29. Tsebe KV, Burnett RJ, Hlungwani NP, Sibara MM, Venter PA, Mphahlele MJ.
The first five years of universal hepatitis B vaccination in South Africa:
evidence for elimination of HBsAg carriage in under 5-year-olds. Vaccine.
2001;19:3919–26. https://doi.org/10.1016/S0264-410X(01)00120-7.
30. Hino K, Katoh Y, Vardas E, Sim J, Okita K, Carman WF. The effect of
introduction of universal childhood hepatitis B immunization in South Africa
on the prevalence of serologically negative hepatitis B virus infection and
the selection of immune escape variants. Vaccine. 2001;19:3912–18. https://
doi.org/10.1016/S0264-410X(01)00121-9.
31. Mphahlele M, Francois G, Kew M, Van Damme P, Hoosen AA, Meheus A.
Epidemiology and Control of Hepatitis B: Implications for Eastern and
Southern Africa. South Afr J Epidemiol Infect. 2002;17:12–7.
32. Schoub BD, Matai U, Singh B, Blackburn NK, Levin JB. Universal
immunization of infants with low doses of a low-cost, plasma-derived
hepatitis B vaccine in South Africa. Bull World Health Organ. 2002;80:277–81.
33. Simani OE, Leroux-Roels G, François G, Burnett RJ, Meheus A, Mphahlele MJ.
Reduced detection and levels of protective antibodies to hepatitis B vaccine
in under 2-year-old HIV positive South African children at a paediatric
outpatient clinic. Vaccine. 2009;27:146–51. https://doi.org/10.1016/j.vaccine.
2008.10.004.
34. Thio CL. Hepatitis B and human immunodeficiency virus coinfection.
Hepatology. 2009;49:138-45. https://doi.org/10.1002/hep.22883.
35. Paganelli M, Stephenne X, Sokal EM. Chronic hepatitis B in children and
adolescents. J Hepatol. 2012;57:885–96. https://doi.org/10.1016/j.jhep.2012.
03.036.
36. Hoffmann CJ, Mashabela F, Cohn S, Hoffmann JD, Lala S, Martinson NA,
et al. Maternal hepatitis B and infant infection among pregnant women
living with HIV in South Africa. J Int AIDS Soc. 2014;17:18871. https://doi.org/
10.7448/IAS.17.1.18871.
37. Chotun N, Nel E, Cotton MF, Andersson MI. Hepatitis B virus infection in
HIV-exposed infants in the Western Cape, South Africa. Vaccine. 2015;33:
4618–22. https://doi.org/10.1016/j.vaccine.2015.06.076.
38. Lee C, Gong Y, Brok J, Boxall EH, Gluud C. Hepatitis B immunisation for
newborn infants of hepatitis B surface antigen-positive mothers. Evid Based
Child Health. 2006;2:67–155.
39. Poovorawan Y, Chongsrisawat V, Theamboonlers A, Srinivasa K, Hutagalung
Y, Bock HL, et al. Long-term benefit of hepatitis B vaccination among
children in Thailand with transient hepatitis B virus infection who were born
to hepatitis B surface antigen-positive mothers. J Infect Dis. 2009;200:33–8.
https://doi.org/10.1086/599331.
40. Evans AA, Cohen C, Huang P, Qian L, London WT, Block JM, et al.
Prevention of perinatal hepatitis B transmission in Haimen City, China:
Results of a community public health initiative. Vaccine. 2015;33:3010–15.
https://doi.org/10.1016/j.vaccine.2015.01.054.
41. Sellier P, Maylin S, Amarsy R, Mazeron MC, Larrouy L, Haïm-Boukobza S,
et al. Untreated highly viraemic pregnant women from Asia or sub‐Saharan
Africa often transmit hepatitis B virus despite serovaccination to newborns.
Liver Int. 2015;35:409–16. https://doi.org/10.1111/liv.12561.
42. Chakvetadze C, Roussin C, Roux J, Mallet V, Petinelli ME, Pol S. Efficacy of
hepatitis B sero-vaccination in newborns of African HBsAg positive mothers.
Vaccine. 2011;29:2846–9. https://doi.org/10.1016/j.vaccine.2011.01.101.
43. Yahyapour Y, Karimi M, Molaei HR, Khoddami E, Mahmoudi M. Active-
passive Immunization Effectiveness Against Hepatitis B Virus in Children
Born to HBsAg Positive Mothers in Amol, North of Iran. Oman Med J. 2011;
26:399–403. https://doi.org/10.5001/omj.2011.103.
44. Köse S, Türken M, Devrim İ, Taner C. Efficacy and safety of lamivudine
treatment in late pregnancy with high HBV DNA: a perspective for mother
and infants. J Infect Dev Ctries. 2011;5:303–6. https://doi.org/10.3855/jidc.
1398.
45. Greenup AJ, Tan PK, Nguyen V, Glass A, Davison S, Chatterjee U, et al.
Efficacy and safety of tenofovir disoproxil fumarate in pregnancy to prevent
perinatal transmission of hepatitis B virus. J Hepatol. 2014;61:502–7. https://
doi.org/10.1016/j.jhep.2014.04.038.
46. Han G, Jiang H, Yue X, Ding Y, Wang CM, Wang GJ, et al. Efficacy and safety
of telbivudine treatment: an open-label, prospective study in pregnant
women for the prevention of perinatal transmission of hepatitis B virus
infection. J Viral Hepat. 2015;22:754–62. https://doi.org/10.1111/jvh.12379.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Tamandjou Tchuem et al. BMC Pediatrics          (2020) 20:563 Page 7 of 7
